Goldstein Dov A MD Buys 25,000 Zero‑Cost Options, Signaling Strong Insider Faith in Gain Therapeutics’ Q3 2026 Phase 2 Breakthrough
Insider option grants at Gain Therapeutics signal confidence in upcoming Phase 2 studies, aligning executives with long‑term shareholder upside.
3 minutes to read